Vitlipid® N Infant

(ergocalciferol, phytomenadione, retinol palmitate, dl-alpha-tocopherol)

​For GB healthcare professionals only. This content contains promotional and brand information.

Scroll down for prescribing information for micronutrient parenteral nutrition (PN) products and further product information. Adverse event reporting details are available at the bottom of this webpage.

Multivitamin preparation of fat-soluble vitamins for intravenous nutrition in infants and children up to 11 years of age.

PN should be monitored, and doses adjusted according to individual patient response. Please refer to the Summary of Product Characteristics before prescribing.

Please note product image is for illustrative purposes only and labelling on actual product may appear differently.

Filename
Prescribing information parenteral nutrition micronutrients.pdf
Size
150 KB
Format
pdf
PN Micronutrient Prescribing Information

Details

  • Vitlipid® N Infant contains vitamins A1, D2, E and K1.
  • Extensive compatibility and stability data with PN regimens are available upon request from our medical information team: Medical.Information-UK@fresenius-kabi.com

 

 1ml contains: 10ml contains: 
Retinolpalmitate corresponding to retinol 
(Vitamin A)
230 IU2300 IU
Ergocalciferol (vitamin D2)40 IU400 IU
dl-alpha-tocopherol (vitamin E)0.7 IU7 IU
Phytomenadione (vitamin K1)20µg200µg

 

​In infants and children up to 11 years of age as a supplement in intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A1, D2, E, K1

Item codeUnit size Case qty
831016221 10ml10

 


Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk Adverse events should also be reported to Fresenius Kabi Limited.  Email: Pharmacovigilance.GB@fresenius-kabi.com

GB-Vitlp-2400005 January 2025 

By entering the Healthcare Professional Area you are confirming you are a GB Healthcare Professional. This area contains promotional information. If you are not a Healthcare Professional you will be directed to the Fresenius Kabi GB Corporate website.

GB-NP-2400163 October 2024